A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE

Project: Other project

Project Details

StatusActive
Effective start/end date1/4/211/3/23

Funding

  • Pfizer, Inc.: $19,183.90